In the last trading session, 1.05 million shares of the Fulcrum Therapeutics Inc. (NASDAQ:FULC) were traded, and its beta was 2.06. Most recently the company’s share price was $3.42, and it changed around $0.35 or 11.40% from the last close, which brings the market valuation of the company to $213.20M. FULC currently trades at a discount to its 52-week high of $15.00, offering almost -338.6% off that amount. The share price’s 52-week low was $2.25, which indicates that the current value has risen by an impressive 34.21% since then. We note from Fulcrum Therapeutics Inc.’s average daily trading volume that its 10-day average is 0.66 million shares, with the 3-month average coming to 1.24 million.
Fulcrum Therapeutics Inc. stock received a consensus recommendation rating of an Overweight, based on a mean score of 2.50. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended FULC as a Hold, whereas 3 deemed it a Buy, and 1 rated it as Underweight. Fulcrum Therapeutics Inc. is expected to report earnings per share of -$0.45 for the current quarter.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Fulcrum Therapeutics Inc. (NASDAQ:FULC) trade information
Instantly FULC has showed a green trend with a performance of 11.40% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.81 on Tuesday, 05/23/23 increased the stock’s daily price by 10.24%. The company’s shares are currently down -53.02% year-to-date, but still down -10.00% over the last five days. On the other hand, Fulcrum Therapeutics Inc. (NASDAQ:FULC) is 29.06% down in the 30-day period. We can see from the shorts that 4.78 million shares have been sold at a short interest cover period of 5.19 day(s).
The consensus price target as assigned by Wall Street analysts is $7.69, which translates to bulls needing to increase their stock price by 55.53% from its current value. Analyst projections state that FULC is forecast to be at a low of $3.00 and a high of $16.00. In order for the stock price to hit the forecast high, the stock would need to plunge -367.84% from its current level, while the stock would need to crash 12.28% from its current level to reach the projected low.
Fulcrum Therapeutics Inc. (FULC) estimates and forecasts
Fulcrum Therapeutics Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -47.30 percent over the past six months and at a 25.41% annual growth rate that is well above the industry average of 11.20%. Moreover, analysts have decided to roll up on their fiscal year 2023 revenue estimates. The rating firms predict that it will gain 45.80% in revenue this quarter, and will report an increase of 5.90% in the next quarter. The year-over-year growth rate is expected to be -53.20%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of $960k in revenue for the current quarter. 7 analysts expect Fulcrum Therapeutics Inc. to make $960k in revenue for the quarter ending Sep 2023. The company’s sales for the same quarters a year ago were $1.88 million and $2.54 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -49.00%. Forecasts for the next quarter put sales growth at -62.20%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -16.50%. Fulcrum Therapeutics Inc. earnings are expected to increase by -6.80% in 2023, but the outlook is positive 6.40% per year for the next five years.
Fulcrum Therapeutics Inc.’s next quarterly earnings report is expected to be released in June.
Fulcrum Therapeutics Inc. (NASDAQ:FULC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.82% of Fulcrum Therapeutics Inc. shares, and 90.43% of them are in the hands of institutional investors. The stock currently has a share float of 95.02%. Fulcrum Therapeutics Inc. stock is held by 169 institutions, with RA Capital Management, L.P. being the largest institutional investor. By Mar 30, 2023, it held 18.80% of the shares, which is about 11.61 million shares worth $33.09 million.
FMR, LLC, with 9.97% or 6.16 million shares worth $17.55 million as of Mar 30, 2023, holds the second largest percentage of outstanding shares.
Fidelity Select Portfolios – Biotechnology and Fidelity Growth Company Fund were the top two Mutual Funds as of Feb 27, 2023. The former held 1.45 million shares worth $8.75 million, making up 2.35% of all outstanding shares. On the other hand, Fidelity Growth Company Fund held roughly 1.33 million shares worth around $8.05 million, which represents about 2.16% of the total shares outstanding.